Table 3 Comparison between AIH patients with and without associated AIT

Sex: N (%)

 Females

33 (68.7)

8 (80)

0.48

 Males

15 (31.3)

2 (20)

Age in years; mean ± SD

11 ± 4.7

12.5 ± 3.5

0.37

Age of onset in years; mean ± SD

6.6 ± 4.1

8.3 ± 3.3

0.22

Mode of presentation: N (%)

 Acute hepatitis

24 (50)

7 (70)

0.69

0.23

 Insidious onset

7 (14.6)

1 (10)

0.69

 Acute liver cell failure

10 (20.8)

1 (10)

0.42

 Complications of chronic liver disease

7 (14.6)

1 (10)

0.69

Symptoms & signs of thyroid affection

 Goiter

0 (0)

1 (10)

0.027^*

 Impaired school performance

12 (25)

6 (60)

0.03^*

 Hyperthermia

0 (0)

1 (10)

0.027^*

 Heat intolerance

0 (0)

1 (10)

0.027^*

Positive family history of AIH

3 (6.3)

1 (10)

0.54

Positive family history of AIT

2 (4.2)

1 (10)

0.44

Family history of ADs

8 (16.7)

3 (30)

0.32

Autoimmune disease association

18 (37.5)

3 (30)

0.65

Weight in Kg < 3^rd percentile

6 (12.5)

0 (0)

0.23

Weight > 97^th percentile

1 (2.1)

0 (0)

0.62

Height in cm < 3^rd percentile

10 (20.8)

2 (20)

0.92

Height > 97^th percentile

1 (2.1)

0 (0)

0.62

BMI kg/m² < 3^rd percentile

2 (4.2)

0 (0)

0.48

BMI > 97^th percentile

1 (2.1)

1 (10)

0.23

Total Ig G at presentation

2755.5 ± 1208

3200.1 ± 440.7

0.41

Total Ig G at study enrollment

1819.7 ± 1208.7

1866 ± 805.7

0.66

Positive ANA at study enrollment

6 (12.5)

0 (0)

0.58

Positive ASMA at study enrollment

23 (47.9)

6 (60)

0.49

Positive anti-LKM antibody at study enrollment

7 (14.6)

0 (0)

0.19

Positive AMA at study enrollment

0 (0)

1 (10)

0.027^*

Positive ANCA at study enrollment

4 (8.3)

1 (10)

1

Type of AIH:

 Seronegative

2 (4.2)

1 (10)

0.35

0.42

 Type I

32 (66.7)

8 (80)

0.42

 Type II

14 (29.2)

1 (10)

0.19

Remission at the time of the study

26 (54.2)

4 (40)

0.42